Related Experiment Video
Updated: Jun 18, 2026

09:38
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
12.1K
Plasma Exchange vs. Immunoadsorption: Effects on Immunological Markers and Predictive Value in Steroid-Refractory MS
Ioannis Vardakas, Johannes Dorst, André Huss1
1University of Ulm, Department of Neurology, Ulm, Germany.
Summary
Immunoadsorption (IA) and plasma exchange (PLEX) differentially impact serum markers in Multiple Sclerosis (MS) patients. Neither IA nor PLEX predicted apheresis response, though IA may more effectively reduce B-cell inflammation.
Area of Science:
- Neuroimmunology
- Biochemistry
Background:
- Limited understanding of neurochemical mechanisms in steroid-refractory Multiple Sclerosis (MS) attacks treated with apheresis.
- Investigating apheresis efficacy in MS requires examining its impact on specific immunological parameters.
Purpose of the Study:
- To compare the effects of immunoadsorption (IA) and plasma exchange (PLEX) on serum immunological markers in MS patients.
- To determine the predictive value of these immunological markers for apheresis response in MS.
Main Methods:
- Analysis of pre- and post-procedural serum samples from 38 MS patients undergoing IA (n=19) or PLEX (n=19) from the IAPEMS trial.
- Quantification of serum immunoglobulins (IgG, IgA, IgM), immunoglobulin free light chains (κ-FLC, λ-FLC), and chemokines (CXCL13, CXCL12).
Main Results:
- Both IA and PLEX significantly reduced serum immunoglobulins (IgG, IgA, IgM) and lambda-FLC.
- IA reduced CXCL12, while PLEX increased CXCL13; IA did not affect κ-FLC, but PLEX did.
- No evaluated serum parameter predicted apheresis response in MS patients.
Conclusions:
- IA and PLEX exert differential effects on serum immunological parameters in MS.
- IA may be more effective in reducing B-cell-mediated inflammation compared to PLEX.
- Further research is needed to correlate these findings with clinical outcomes and B-cell therapy efficacy in MS.

